InFocus: Cell & Gene Therapy
2020
Produced in association with Novartis, InFocus Cell & Gene Therapy examines the remarkable progress of cell and gene therapies in recent years. Fast turning into a powerful engine of value creation for drug makers and representing a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses, in the last five to ten years, for instance, we have witnessed innovative pharma investing deeply in high-risk frontier research involving stem cells and the harnessing of a patient’s own immune system to attack the onset of a disease.
This exclusive new eBook features the insights of regulators, policymakers, key opinion leaders, and representatives of the leading companies in cell and gene therapy from across Europe, the USA, and Asia. Also included are a full list of product approvals by geography, as well as summations of the investment landscape for cell and gene therapies, manufacturing challenges, and regulatory issues.
Produced in association with Novartis, InFocus Cell & Gene Therapy examines the remarkable progress of cell and gene therapies in recent years. Fast turning into a powerful engine of value creation for drug makers and representing a paradigm shift in the treatment of some of the world’s most devastating and intractable illnesses, in the last five to ten years, for instance, we have witnessed innovative pharma investing deeply in high-risk frontier research involving stem cells and the harnessing of a patient’s own immune system to attack the onset of a disease.
This exclusive new eBook features the insights of regulators, policymakers, key opinion leaders, and representatives of the leading companies in cell and gene therapy from across Europe, the USA, and Asia. Also included are a full list of product approvals by geography, as well as summations of the investment landscape for cell and gene therapies, manufacturing challenges, and regulatory issues.
